Strategies for the enhancement of recombinant protein production from mammalian cells by growth arrest
Abstract
Methods to increase the production of recombinant proteins in mammalian cell cultures have been developed which reduce in-culture growth through prohibiting progression of the cell cycle. This arrest increases the proportion of cells in the G1-phase of the cell cycle, and subsequently increases their specific productivity (Q(P)). Through careful balancing of the decreased growth rate with an increased Q(P), multi-fold increases in recombinant protein yield can be achieved. Induction of this arrest can occur through the addition of cytostatic chemical agents (NaBu or DMSO), over-expression of cell cycle inhibitory proteins (p21(Cip1) or p27(Kip1)), or through control of the culture environment (mild hypothermic temperatures). While all these controlled proliferation strategies have been developed independently, they all aim to control cell proliferation through a shared mechanism; the direct or indirect up-regulation of members of the cyclin-dependent kinase inhibitor (CKI) family. This review highlights the shared biology of these three controlled proliferation strategies, and their contribution towards bioprocess development for recombinant production from animal cell cultures.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Use of histone deacetylase inhibitors such as NaB and VPA may also have undesired secondary effects, such as blocking cell cycle or inducing apoptosis.
“However, the use of these inhibitors may also have undesired secondary effects, such as blocking cell cycle or inducing apoptosis (Sung et al., 2004;Jiang and Sharfstein, 2008;Sunley and Butler, 2010).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Sunley and Butler, 2010
Cites
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862 · see citing works
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836 · see citing works
Jiang, Z., & Sharfstein, S. T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21726 · Cited by 118 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · see citing works
Park, J. H., Noh, S. M., Woo, J. R., Kim, J. W., & Lee, G. M. (2016) · Biotechnology Journal · doi:10.1002/biot.201500327 · Cited by 81 · see citing works
Bravo-Venegas, J., Rodriguez-Siza, J., Vergara, M., Torres, M., Dickson, A., Toledo, J. R., Molina, M. C., Hermoso, M. A., Berríos, J., & Altamirano, C. (2026) · mAbs · doi:10.1080/19420862.2026.2643039 · Cited by 3 · see citing works
“These include chemicals that induce, either independently or in combination, cell cycle arrest (e.g., cyclin-dependent kinase inhibitors), 73 chemical chaperones, 74 ER stress inhibitors, 70 and histone deacetylase inhibitors (HDAC) such as NaBu or valeric acid.”
- Authors
- Sunley, K., & Butler, M.
- Affiliations
- University of Manitoba (CA)
- Corresponding author
- Butler, Michael
- ORCID
- Butler, Michael
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 28
- Issue
- 3
- Pages
- 385-394
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W1985719186
- Cited by
- 136
- References
- 3
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 10 · 2023: 6 · 2022: 4 · 2021: 6 · 2020: 9 · 2019: 13 · 2018: 8 · 2017: 8 · 2016: 4 · 2015: 8 · 2014: 15 · 2013: 16 · 2012: 9
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biotechnology Advances (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- recombinant protein expression, mammalian cell culture, growth arrest, cell cycle arrest, G1 phase, specific productivity, cytostatic agents, sodium butyrate, dimethyl sulfoxide, p21, p27, cyclin-dependent kinase inhibitors, bioprocess development
- MeSH terms
- Animals, Cell Cycle, Humans, Recombinant Proteins, Protein Engineering, Cell Cycle Proteins, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review